Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Alan P Skarbnik"'
Autor:
Alan Z. Skarbnik, Krish Patel
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Follicular lymphoma (FL) is the second most common lymphoma in the United States and is characterized by a variable clinical course, disease heterogeneity, and a relapse-and-remittance pattern historically accompanied by successive shortening of clin
Externí odkaz:
https://doaj.org/article/5e111dca403e4a0fbead160cfaf827df
Autor:
Antonio Cuneo, Anthony R. Mato, Gian Matteo Rigolin, Alfonso Piciocchi, Massimo Gentile, Luca Laurenti, John N. Allan, John M. Pagel, Danielle M. Brander, Brian T. Hill, Allison Winter, Nicole Lamanna, Constantine S. Tam, Ryan Jacobs, Frederick Lansigan, Paul M. Barr, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Alison R. Sehgal, Stephen J. Schuster, Nirav N. Shah, Chaitra S. Ujjani, Lindsey Roeker, Ester Maria Orlandi, Atto Billio, Livio Trentin, Martin Spacek, Monia Marchetti, Alessandra Tedeschi, Fiorella Ilariucci, Gianluca Gaidano, Michael Doubek, Lucia Farina, Stefano Molica, Francesco Di Raimondo, Marta Coscia, Francesca Romana Mauro, Javier de la Serna, Angeles Medina Perez, Isacco Ferrarini, Giuseppe Cimino, Maurizio Cavallari, Rosalba Cucci, Marco Vignetti, Robin Foà, Paolo Ghia, the GIMEMA, European Research Initiative (ERIC) on CLL, US study group
Publikováno v:
Cancer Medicine, Vol 9, Iss 22, Pp 8468-8479 (2020)
Abstract Limited information is available on the efficacy of front‐line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real‐world patie
Externí odkaz:
https://doaj.org/article/51d4f3af2edb4e18930e0b7ba14d8eff
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 4, Iss , Pp 100087- (2021)
Although non-Hodgkin lymphoma (NHL), a cancer of the lymph nodes, may at times present as malignant pleural, pericardial, or peritoneal primary effusions, Primary Effusion Lymphoma (PEL) is a rare and aggressive subtype which lacks any distinguishabl
Externí odkaz:
https://doaj.org/article/98b8eae2304d46399e58b8d5ed9c155d
Autor:
David Bernard Miklos, Mohammad Abu Zaid, Julian P. Cooney, Jörn C. Albring, Mary Flowers, Alan P. Skarbnik, Ibrahim Yakoub-Agha, Bor-Sheng Ko, Benedetto Bruno, Edmund K. Waller, Jean Yared, Sang Kyun Sohn, Claude-Eric Bulabois, Takanori Teshima, David Jacobsohn, Hildegard Greinix, Ahmad Mokatrin, Yihua Lee, Justin T. Wahlstrom, Lori Styles, Gerard Socie
Publikováno v:
Journal of Clinical Oncology. 41:1876-1887
PURPOSE To present primary and final analyses from the randomized, double-blind, placebo-controlled, phase III iNTEGRATE study, which evaluated the safety and efficacy of ibrutinib with prednisone in previously untreated patients with chronic graft-v
Autor:
Anthony R. Mato, Amy A. Kirkwood, Anna Schuh, Neil Bailey, Andrea Sitlinger, Laurie Pearson, Sivraj Muralikrishnan, Andre Goy, Ryan Jacobs, Annalynn M. Williams, John M. Pagel, Charlene Kabel, Hannah Morse, Colleen Dorsey, Joanna Rhodes, Allison M. Winter, Hande H. Tuncer, Chaitra S. Ujjani, Mazyar Shadman, Alan P. Skarbnik, Paul M. Barr, Catherine C. Coombs, Arun K. Singavi, Nicole Lamanna, Bruce D. Cheson, Maryam Yazdy, Frederick Lansigan, Nirav N. Shah, Brian T. Hill, Chadi Nabhan, Stephen J. Schuster, John N. Allan, Danielle M. Brander, Toby A. Eyre, Christopher P. Fox, Lindsey E. Roeker
Purpose:Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1141a6ec125abdac6fd3f47dbf2ea5e3
https://doi.org/10.1158/1078-0432.c.6528248
https://doi.org/10.1158/1078-0432.c.6528248
Autor:
Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, Anthony R. Mato
Purpose:Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood.Experimental Des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e72e05cfed97bbc9e2e47db93b397aae
https://doi.org/10.1158/1078-0432.c.6528851
https://doi.org/10.1158/1078-0432.c.6528851
Autor:
Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, Anthony R. Mato
Supplemental Figure 2: Progression free survival of patients without prior BTKi exposure who had progressed on venetoclax and were then treated with BTKi.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::391825ca38ac12df33b7f05e19ba469f
https://doi.org/10.1158/1078-0432.22474643.v1
https://doi.org/10.1158/1078-0432.22474643.v1
Autor:
Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, Anthony R. Mato
Supplemental Figure 1: Overall survival of entire cohort from initiation of venetoclax.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48f28a1d557f9e1d57cd60895ef876dc
https://doi.org/10.1158/1078-0432.22474646.v1
https://doi.org/10.1158/1078-0432.22474646.v1
Autor:
Anthony R. Mato, Amy A. Kirkwood, Anna Schuh, Neil Bailey, Andrea Sitlinger, Laurie Pearson, Sivraj Muralikrishnan, Andre Goy, Ryan Jacobs, Annalynn M. Williams, John M. Pagel, Charlene Kabel, Hannah Morse, Colleen Dorsey, Joanna Rhodes, Allison M. Winter, Hande H. Tuncer, Chaitra S. Ujjani, Mazyar Shadman, Alan P. Skarbnik, Paul M. Barr, Catherine C. Coombs, Arun K. Singavi, Nicole Lamanna, Bruce D. Cheson, Maryam Yazdy, Frederick Lansigan, Nirav N. Shah, Brian T. Hill, Chadi Nabhan, Stephen J. Schuster, John N. Allan, Danielle M. Brander, Toby A. Eyre, Christopher P. Fox, Lindsey E. Roeker
Supplemental Table 1 and Supplemental Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07586467baaefab6a3670db6e220430f
https://doi.org/10.1158/1078-0432.22472513
https://doi.org/10.1158/1078-0432.22472513
Autor:
Meghan C. Thompson, Andre Goy, Chan Yoon Cheah, Matthew S. Davids, Neil E. Kay, Chadi Nabhan, Constantine S. Tam, Mazyar Shadman, Anthony R. Mato, Kerry A. Rogers, Lindsey E. Roeker, Arnon P. Kater, John F. Seymour, John M. Pagel, Joanna Rhodes, Clare Sun, Alan P Skarbnik, Catherine C. Coombs, Toby A. Eyre, Jennifer R. Brown, Jennifer A. Woyach, Chaitra Ujjani, Stephen J. Schuster, Susan O'Brien, Danielle M. Brander, Nicole Lamanna, Nitin Jain, Jeff P. Sharman
Publikováno v:
Clin Cancer Res
Clinical Cancer Research, 28(4), 603-608. American Association for Cancer Research Inc.
Clinical cancer research, 28(4), 603-608. American Association for Cancer Research Inc.
Mato, A R, Davids, M S, Sharman, J, Roeker, L E, Kay, N, Kater, A P, Rogers, K, Thompson, M C, Rhodes, J, Goy, A, Skarbnik, A, Schuster, S J, Tam, C S, Eyre, T A, O'Brien, S, Nabhan, C, Lamanna, N, Sun, C, Shadman, M, Pagel, J M, Ujjani, C, Brander, D, Coombs, C C, Jain, N, Cheah, C Y, Brown, J R, Seymour, J F & Woyach, J A 2022, ' Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL : “What's Past Is Prologue” (Shakespeare) ', Clinical Cancer Research, vol. 28, no. 4, pp. 603-608 . https://doi.org/10.1158/1078-0432.CCR-21-1237
Clinical Cancer Research, 28(4), 603-608. American Association for Cancer Research Inc.
Clinical cancer research, 28(4), 603-608. American Association for Cancer Research Inc.
Mato, A R, Davids, M S, Sharman, J, Roeker, L E, Kay, N, Kater, A P, Rogers, K, Thompson, M C, Rhodes, J, Goy, A, Skarbnik, A, Schuster, S J, Tam, C S, Eyre, T A, O'Brien, S, Nabhan, C, Lamanna, N, Sun, C, Shadman, M, Pagel, J M, Ujjani, C, Brander, D, Coombs, C C, Jain, N, Cheah, C Y, Brown, J R, Seymour, J F & Woyach, J A 2022, ' Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL : “What's Past Is Prologue” (Shakespeare) ', Clinical Cancer Research, vol. 28, no. 4, pp. 603-608 . https://doi.org/10.1158/1078-0432.CCR-21-1237
The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance